111 results on '"Sugimoto, Masamichi"'
Search Results
2. Identification of fibrocyte cluster in tumors reveals the role in antitumor immunity by PD-L1 blockade
3. PD-L1 blockade exhibits anti-tumor effect on brain metastasis by activating CD8+ T cells in hematogenous metastasis model with lymphocyte infusion
4. Dysfunction of sinus macrophages in tumor‐bearing host induces resistance to immunotherapy
5. Both T cell priming in lymph node and CXCR3-dependent migration are the key events for predicting the response of atezolizumab
6. Bevacizumab suppresses the growth of established non-small-cell lung cancer brain metastases in a hematogenous brain metastasis model
7. Dysfunction of sinus macrophages in tumor‐bearing host induces resistance to immunotherapy.
8. Supplementary Figure 7 from Combining Onartuzumab with Erlotinib Inhibits Growth of Non–Small Cell Lung Cancer with Activating EGFR Mutations and HGF Overexpression
9. Supplementary Information from Combining Onartuzumab with Erlotinib Inhibits Growth of Non–Small Cell Lung Cancer with Activating EGFR Mutations and HGF Overexpression
10. Data from Combining Onartuzumab with Erlotinib Inhibits Growth of Non–Small Cell Lung Cancer with Activating EGFR Mutations and HGF Overexpression
11. Supplementary Figure 2 from Combining Onartuzumab with Erlotinib Inhibits Growth of Non–Small Cell Lung Cancer with Activating EGFR Mutations and HGF Overexpression
12. Supplementary Figure 3 from Combining Onartuzumab with Erlotinib Inhibits Growth of Non–Small Cell Lung Cancer with Activating EGFR Mutations and HGF Overexpression
13. Supplementary Figure 5 from Combining Onartuzumab with Erlotinib Inhibits Growth of Non–Small Cell Lung Cancer with Activating EGFR Mutations and HGF Overexpression
14. Supplementary Figure 6 from Combining Onartuzumab with Erlotinib Inhibits Growth of Non–Small Cell Lung Cancer with Activating EGFR Mutations and HGF Overexpression
15. Supplementary Figure 1 from Combining Onartuzumab with Erlotinib Inhibits Growth of Non–Small Cell Lung Cancer with Activating EGFR Mutations and HGF Overexpression
16. Supplementary Figure 4 from Combining Onartuzumab with Erlotinib Inhibits Growth of Non–Small Cell Lung Cancer with Activating EGFR Mutations and HGF Overexpression
17. Effect of Bevacizumab on a Human Breast Cancer Model that Exhibited Palbociclib-resistance by RB Knockout
18. Blockade of PD-1/PD-L1 Pathway Enhances the Antigen-Presenting Capacity of Fibrocytes
19. Anti‑VEGF antibody triggers the effect of anti‑PD‑L1 antibody in PD‑L1lowand immune desert‑like mouse tumors
20. Anti-VEGF Antibody Protects against Alveolar Exudate Leakage Caused by Vascular Hyperpermeability, Resulting in Mitigation of Pneumonitis Induced by Immunotherapy
21. PD-L1 blockade exhibits anti-tumor effect on brain metastasis by activating CD8+ T cells in hematogenous metastasis model with lymphocyte infusion
22. PD-L1 blockade exhibits anti-tumor effect on brain metastasis by activating CD8+ T cells in hematogenous metastasis model with lymphocyte infusion.
23. The role of fibrocyte-like cells in combination treatment of immune checkpoint inhibitor with antiangiogenic agents
24. A defucosylated anti-CD317 antibody exhibited enhanced antibody-dependent cellular cytotoxicity against primary myeloma cells in the presence of effectors from patients
25. Abstract B046: Addition of anti-VEGF overcomes the anti-PD-L1 refractoriness in a OV2944-HM-1 tumor model
26. Bevacizumab suppresses the growth of established non-small-cell lung cancer brain metastases in a hematogenous brain metastasis model
27. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family
28. Anti–Interleukin-6 Receptor Antibody Therapy Reduces Vascular Endothelial Growth Factor Production in Rheumatoid Arthritis
29. Abstract 4995: Mechanism of action of anti-PD-L1 antibody in a PD-L1-negative and immune desert-like tumor model
30. Sustained effect of continuous treatment with bevacizumab following bevacizumab in combination with chemotherapy in a human ovarian clear cell carcinoma xenograft model
31. Cisplatin Augments Antitumor T-Cell Responses Leading to a Potent Therapeutic Effect in Combination With PD-L1 Blockade
32. Topoisomerase I inhibitor, irinotecan, depletes regulatory T cells and up-regulates MHC class I and PD-L1 expression, resulting in a supra-additive antitumor effect when combined with anti-PD-L1 antibodies
33. Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model
34. Importance of Bevacizumab Maintenance Following Combination Chemotherapy in Human Non–small Cell Lung Cancer Xenograft Models
35. Continuous administration of bevacizumab plus capecitabine, even after acquired resistance to bevacizumab, restored anti-angiogenic and antitumor effect in a human colorectal cancer xenograft model
36. Combining Onartuzumab with Erlotinib Inhibits Growth of Non–Small Cell Lung Cancer with Activating EGFR Mutations and HGF Overexpression
37. Generation of a humanized anti-glypican 3 antibody by CDR grafting and stability optimization
38. Optimization of tissue processing for immunohistochemistry for the detection of human glypican-3
39. Abstract 2426: Anti-Glypican3 antibody for treatment of human liver cancer
40. Histopathological analyses of the antitumor activity of anti-glypican-3 antibody (GC33) in human liver cancer xenograft models: The essential role of macrophages
41. Anti-glypican 3 antibodies cause ADCC against human hepatocellular carcinoma cells
42. Anti–Glypican 3 Antibody as a Potential Antitumor Agent for Human Liver Cancer
43. Statistical Methods Used to Determine Drug Consumption in New Hospice Ward
44. 2D7 diabody bound to the α2 domain of HLA class I efficiently induces caspase-independent cell death against malignant and activated lymphoid cells
45. Human interleukin-6 induces human herpesvirus-8 replication in a body cavity-based lymphoma cell line
46. Anti-VEGF antibody triggers the effect of anti-PD-L1 antibody in PD-L1low and immune desert-like mouse tumors.
47. Tumoricidal Activity of Lymphotoxin (Tumor Necrosis Factor β) In Vivo.
48. Human Macrophage‐Activating Factors for Cytotoxicity
49. The Production of a Cytotoxic Factor by Mouse Peritoneal Macrophages and Macrophage Hybridomas Treated with Various Stimulating Agents
50. Purification and characterization of a cytotoxic factor produced by a mouse macrophage hybridoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.